Abstract LB-031: Deciphering distinct roles of RASA2 in melanomagenesis: Cancer Research

Rand Arafeh, Nouar Qutob, Rafi Rafi Emmanuel, Jason Madore, Abdel Elkahloun, James S. James S. Wilmott, Jared J. Gartner, Antonella Di Pizio, Ron Rotkopf, Ken Dutton-Regester, Victoria Hill, Antonia Pritchard, Jimmy C. Lin, Steven A Rosenberg, Javed Khan, Shifra Ben-Dor, Masha Y. Masha Y. Niv, Igor Ulitsky, Graham J Mann, Richard A. ScolyerNicholas K. Hayward, Yardena Samuels

Research output: Contribution to journalMeeting abstract

Abstract

Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DCMelanoma is the deadliest form of human skin cancer. The incidence of melanoma continues to rise. Recent advances in knowledge of melanoma genetics, genomics and biology has led to an optimistic view of the therapeutic outlook for melanoma patients. We analyzed sequence data from >500 melanoma genomes/exomes to identify novel tumor suppressor genes in melanoma. RASA2 was identified as the most highly somatically mutated novel tumor suppressor gene. RASA2 was mutated in 5% of melanomas and deleted in an additional 16.4% of cases. RASA2 is a GTPase Activating Protein (GAP) that regulates RAS; which is one of the most highly mutated oncogenes in melanoma but drugs targeting RAS have as yet shown poor efficacy. The role of RASA2 has not been investigated in melanoma. NF1, which encodes another RAS- specific GAP, was found to be frequently mutated in melanoma. Interestingly, mutations in RASA2 and NF1 co-occur in the same patients with high frequency. We plan to elucidate the roles of RASA2 in melanomagenesis and to understand why RASA2 and NF1 mutations co-occur despite the fact that both proteins are RasGAPs. Ras includes three isoforms: NRas, KRas and HRas. Our preliminary data show that RASA2 is more specific to NRAS and that NF1 is more specific to KRAS and HRAS. This finding highlights the existence of a paradigm of cooperativity in which combined loss of multiple negative regulators (RASA2 and NF1) of the RAS pathway is required for melanoma development. Therefore, this type of enhancement of RAS signaling is possibly selected for in some melanomas. We will apply a proteomic screen using BioID to identify RASA2 and NF1 binding partners to provide insights into the functional effects and consequences of alterations in RASA2 and NF1. We expect that these studies will not only identify the cellular components that contribute to the Ras signaling pathway but will also identify potential novel therapeutic targets.Citation Format: Rand Arafeh, Nouar Qutob, Rafi Rafi Emmanuel, Jason Madore, Abdel Elkahloun, James S. James S. Wilmott, Jared J. Gartner, Antonella Di Pizio, Ron Rotkopf, Ken Dutton-Regester, Victoria Hill, Antonia Pritchard, Jimmy C. Lin, Steven A Rosenberg, Javed Khan, Shifra Ben-Dor, Masha Y. Masha Y. Niv, Igor Ulitsky, Graham J Mann, Richard A. Scolyer, Nicholas K. Hayward, Yardena Samuels. Deciphering distinct roles of RASA2 in melanomagenesis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr LB-031. doi:10.1158/1538-7445.AM2017-LB-031
Original languageEnglish
Pages (from-to)LB-031-LB-031
JournalCancer Research
Volume77
Issue number13 Suppl
DOIs
Publication statusPublished - 2017

Fingerprint Dive into the research topics of 'Abstract LB-031: Deciphering distinct roles of RASA2 in melanomagenesis: Cancer Research'. Together they form a unique fingerprint.

  • Cite this

    Arafeh, R., Qutob, N., Emmanuel, R. R., Madore, J., Elkahloun, A., Wilmott, J. S. J. S., Gartner, J. J., Pizio, A. D., Rotkopf, R., Dutton-Regester, K., Hill, V., Pritchard, A., Lin, J. C., Rosenberg, S. A., Khan, J., Ben-Dor, S., Niv, M. Y. M. Y., Ulitsky, I., Mann, G. J., ... Samuels, Y. (2017). Abstract LB-031: Deciphering distinct roles of RASA2 in melanomagenesis: Cancer Research. Cancer Research, 77(13 Suppl), LB-031-LB-031. https://doi.org/10.1158/1538-7445.Am2017-lb-031